Scholarlink

Purpose of Review <p> This review highlights advances in the diagnosis, risk stratification, and management of pleuroparenchymal fibroelastosis (PPFE), emphasizing its growing recognition as a late complication of cancer therapy and a progressive pattern of fibrotic lung remodeling.&#xa0;</p> Recent Findings <p> PPFE is increasingly recognized across a broad range clinical settings, supporting a shared fibroelastotic response to chronic lung injury. In oncologic survivorship populations, prolonged latency contributes to delayed recognition. Recent studies using quantitative imaging have improved characterization of structural progression and further demonstrated discordance between radiographic disease burden and physiologic measures. Emerging assessment frameworks propose integrating radiographic progression, nutritional status, and clinical trajectory into longitudinal disease evaluation.&#xa0;</p> Summary <p> Early recognition of PPFE remains challenging. The growing population of pediatric cancer survivors reframes PPFE as a late effect of prior therapy with important implications for long-term surveillance and transition of care. Improved, multidimensional frameworks may improve prognostication and help guide management strategies.&#xa0;</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pleuroparenchymal Fibroelastosis: Clinical Recognition, Risk Stratification, and Management in the Era of Cancer Survivorship

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月17日

查看全文
  • Valeria Santibanez

摘要

Purpose of Review

This review highlights advances in the diagnosis, risk stratification, and management of pleuroparenchymal fibroelastosis (PPFE), emphasizing its growing recognition as a late complication of cancer therapy and a progressive pattern of fibrotic lung remodeling. 

Recent Findings

PPFE is increasingly recognized across a broad range clinical settings, supporting a shared fibroelastotic response to chronic lung injury. In oncologic survivorship populations, prolonged latency contributes to delayed recognition. Recent studies using quantitative imaging have improved characterization of structural progression and further demonstrated discordance between radiographic disease burden and physiologic measures. Emerging assessment frameworks propose integrating radiographic progression, nutritional status, and clinical trajectory into longitudinal disease evaluation. 

Summary

Early recognition of PPFE remains challenging. The growing population of pediatric cancer survivors reframes PPFE as a late effect of prior therapy with important implications for long-term surveillance and transition of care. Improved, multidimensional frameworks may improve prognostication and help guide management strategies.